New Alzheimer’s Vaccine ALZ-101 Moves to Phase II After FDA Approval

Swedish biopharmaceutical company Alzinova secured FDA approval to initiate a Phase II clinical trial for ALZ-101, a vaccine candidate targeting toxic amyloid-beta oligomers implicated in Alzheimer’s disease. Following encouraging Phase Ib safety and immunogenicity data, the upcoming trial will evaluate ALZ-101’s efficacy in a larger patient population in the U.S. This advancement represents a critical step toward a potential therapeutic option addressing the early pathological drivers of Alzheimer’s disease progression.